Litcius/Paper detail

How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C

Anjali Sharathkumar, E. Vincent S. Faustino, Clifford M. Takemoto

2021Pediatric Blood & Cancer39 citationsDOIOpen Access PDF

Abstract

Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 (COVID-19). While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.

Topics & Concepts

MedicineCoagulopathyThrombosisCoronavirus disease 2019 (COVID-19)Intensive care medicineComplicationDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMEDLINEMultiorgan failureInfectious disease (medical specialty)Internal medicinePathologyPolitical scienceOutbreakLawKawasaki Disease and Coronary ComplicationsCOVID-19 Clinical Research StudiesBlood Coagulation and Thrombosis Mechanisms
How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C | Litcius